お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
939940

コンパニオン診断市場 - 未来の診断技術:カスタム型の予測・分析 (資金源別・用途別)、新型コロナウイルス感染症 (Covid-19) の影響、エグゼクティブ・コンサルタント向け提言 (2020~2024年)

Companion Diagnostic Markets - the Future of Diagnostics. by Funding Source and Application with Customized Forecasting/analysis, Covid Updates, and Executive and Consultant Guides 2020-2024

出版日: | 発行: Howe Sound Research | ページ情報: 英文 429 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
コンパニオン診断市場 - 未来の診断技術:カスタム型の予測・分析 (資金源別・用途別)、新型コロナウイルス感染症 (Covid-19) の影響、エグゼクティブ・コンサルタント向け提言 (2020~2024年)
出版日: 2020年06月03日
発行: Howe Sound Research
ページ情報: 英文 429 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

コンパニオン診断は、診断業界に革命を起こそうとしています。市場はついに研究室を出て臨床現場へと移行しています。腫瘍、特にがん免疫腫瘍学が先導しています。そして、FDAはこの将来の診断技術への扉を開いています。一方で、新型コロナウイルス感染症 (Covid-19) の感染拡大が医療市場に多大な影響を与えた結果、特殊がん検査の需要が減少しています。

当レポートでは、コンパニオン診断の今後の技術進歩・市場成長の見通しについて分析し、技術的な概略や主な活用分野、今後の医療現場に及ぼす影響力、昨今の主な開発・製品上市の動き、主要企業のプロファイルと主力製品、今後の市場規模の動向見通し、地域別・用途別・資金源別の詳細動向、新型コロナウイルス感染症 (Covid-19) 発生の影響、といった情報を取りまとめてお届けいたします。

目次

i. コンパニオン診断市場:戦略的状況分析

ii. エグゼクティブ・マーケティング・販売・ビジネス開発スタッフ向け提言

iii. 経営コンサルタント・投資顧問向け提言

第1章 イントロダクション、市場の定義

第2章 市場概要

  • ダイナミックな市場における参入企業
    • 教育・研究機関
    • 診断検査の開発業者
    • 計測装置のサプライヤー
    • 試薬の流通業者・サプライヤー
    • 独立系の検査室
    • 国営/公営の検査室
    • 院内検査室
    • 開業医
    • 監査機関
    • 認証機関
  • 個別化医療とコンパニオン診断
    • 基本
    • 方法
    • 疾病リスク評価
    • 用途
    • 診断と侵襲
    • 医薬品の開発と使用
    • 呼吸プロテオミクス
    • がんゲノミクス
    • 集団検診
    • 課題
    • 規制監督
    • 知的財産権
    • 償還方針
    • 患者のプライバシーと機密性
  • 染色体、遺伝子、エピジェネティクス
  • がん遺伝子
    • 生殖細胞と体細胞
    • 臨床的役割の変化
  • 産業の構造が役割を果たす
    • 新規医薬品向け資金市場
    • 規模の経済
    • 開業医
    • 医師とPOCT (ポイントオブケア治療)

第3章 市場動向

  • 市場成長の促進要因
  • 市場成長の抑制要因
  • 計装と自動化
  • 診断技術の開発
    • 次世代シーケンシング:革命の促進
    • 単一細胞ゲノミクス:状況の変革
    • 薬理ゲノミクス:診断と治療の一体化
    • CGES検査:新世界の開拓
    • バイオチップ/巨大磁気抵抗ベースのアッセイ

第4章 コンパニオン診断:近年の進捗状況

  • 当セクションの重要性と活用方法

第5章 主要企業のプロフィール

  • 10x Genomics, Inc.
  • Abbott Diagnostics
  • AccuraGen Inc
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioIVT
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • Castle Biosciences, Inc.
  • CellMax Life
  • Cepheid (now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fabric Genomics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine (now Roche)
  • Freenome
  • FUJIFILM Wako Diagnostics
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd
  • Genomic Health
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Miltenyi Biotec
  • MIODx
  • miR Scientific
  • Molecular MD
  • MyCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Ortho Clinical Diagnostics
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostics
  • Screencell
  • Sense Biodetection.
  • Serametrix
  • Siemens Healthineers
  • Silicon Biosystems
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singulomics
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Todos Medical
  • Trovagene
  • Volition
  • Vortex Biosciences

第6章 世界のコンパニオン診断市場

  • 国別分析:概要
  • 用途別分析:概要
  • 資金源の動向/予測:概要

第7章 世界のコンパニオン診断市場:用途別

  • がん
  • 神経症
  • 循環器疾患
  • その他の用途

第8章 世界のコンパニオン診断市場:資金源別

  • 製薬企業
  • ベンチャーキャピタル
  • 臨床医療機関
  • その他

付録

図表

Table of Tables

  • Table 1 Lab Spending 2014 to 2024
  • Table 2 Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
  • Table 3 Market Players by Type
  • Table 4 The Base Pairs
  • Table 5 Five Factors Driving Growth
  • Table 6 Four Factors Limiting Growth
  • Table 7 Key Diagnostic Laboratory Technology Trends
  • Table 8 Next Generation Sequencing Technologies - Speed and Cost
  • Table 9 - Global Companion Diagnostic Market by Region
  • Table 10 Global Market by Application
  • Table 11 Global Market by Funding Source
  • Table 12 Oncology by Country
  • Table 13 Neurology by Country
  • Table 14 Cardiology by Country
  • Table 15 Other Application by Country
  • Table 16 Pharmaceutical by Country
  • Table 17 Venture by Country
  • Table 18 Clinical by Country
  • Table 19 Other Funding by Country
  • Table 22 Pharmacogenomic Biomarkers

Table of Figures

  • Figure 1 FDA Approved Companion Diagnostics
  • Figure 2 Clinical Lab Spending 2014 to 2024
  • Figure 3 Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
  • Figure 4 DNA Strands and Chromosomes
  • Figure 5 Karyogram of Human Chromosomes
  • Figure 6 Size of Various Genomes
  • Figure 7 Germline vs Somatic Mutations
  • Figure 8 Comparing Genomic Diagnostic and Traditional Testing
  • Figure 9 Percentage of World Population Over 65
  • Figure 10 2019 Global Market Density Chart
  • Figure 11 CDx Market by Application - 2019 vs. 2024
  • Figure 12 CDx Market by Application 2019
  • Figure 13 CDx Market by Application 2024
  • Figure 14 Application Type Share by Year
  • Figure 15 Funding Source - 2019 vs. 2024
  • Figure 16 Funding Source Market 2019
  • Figure 17 Funding Source Market 2024
  • Figure 18 Funding Source Share by Year
  • Figure 19 Oncology Growth
  • Figure 20 Neurology Growth
  • Figure 21 Cardiology Growth
  • Figure 22 Other Application Growth
  • Figure 23 Pharmaceutical Growth
  • Figure 24 Venture Growth
  • Figure 25 Clinical Growth
  • Figure 26 Other Funding Growth
  • Figure 27 2020 Clinical Laboratory Fee Schedule
目次

OVERVIEW:

Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market.

Will Personalized Companion Diagnostics become the norm for diagnostics?

Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost of molecular diagnostics continues to fall.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country or specific area in the world is available to purchasers of the report.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Companion Diagnostic Market - Strategic Situation Analysis

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 What are Companion Diagnostics?
  • 1.2 The Personalized Medicine Revolution
  • 1.3 Market Definition
    • 1.3.1 Revenue Market Size
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 A Spending Perspective on Clinical Laboratory Testing
    • 1.5.1 U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

  • 2.1 Players in a Dynamic Market
    • 2.1.1 Academic Research Lab
    • 2.1.2 Diagnostic Test Developer
    • 2.1.3 Instrumentation Supplier
    • 2.1.4 Distributor and Reagent Supplier
    • 2.1.5 Independent Testing Lab
    • 2.1.6 Public National/regional lab
    • 2.1.7 Hospital lab
    • 2.1.8 Physician Office Labs
    • 2.1.9 Audit Body
    • 2.1.10 Certification Body
  • 2.2 Personalized Medicine and Companion Diagnostics
    • 2.2.1 Basics
    • 2.2.2 Method
    • 2.2.3 Disease risk assessment
    • 2.2.4 Applications
    • 2.2.5 Diagnosis and intervention
      • 2.2.5.1 Companion Diagnostics
    • 2.2.6 Drug development and usage
    • 2.2.7 Respiratory proteomics
    • 2.2.8 Cancer genomics
    • 2.2.9 Population screening
    • 2.2.10 Challenges
    • 2.2.11 Regulatory oversight
    • 2.2.12 Intellectual property rights
    • 2.2.13 Reimbursement policies
    • 2.2.14 Patient privacy and confidentiality
  • 2.3 Chromosomes, Genes and Epigenetics
    • 2.3.1 Chromosomes
    • 2.3.2 Genes
    • 2.3.3 Epigenetics
  • 2.4 Cancer Genes
    • 2.4.1 Germline vs Somatic
    • 2.4.2 Changing Clinical Role
  • 2.5 Structure of Industry Plays a Part
    • 2.5.1 New Pharmaceutical Funding Market
    • 2.5.2 Economies of Scale
      • 2.5.2.1 Hospital vs. Central Lab
    • 2.5.3 Physician Office Labs
    • 2.5.4 Physicians and POCT

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Level of Care
    • 3.1.2 Immuno-oncology
    • 3.1.3 Liability
    • 3.1.4 Aging Population
  • 3.2 Factors Limiting Growth
    • 3.2.1 State of knowledge
    • 3.2.2 Genetic Blizzard.
    • 3.2.3 Protocol Resistance
    • 3.2.4 Regulation and coverage
  • 3.3 Instrumentation and Automation
    • 3.3.1 Instruments Key to Market Share
    • 3.3.2 Bioinformatics Plays a Role
  • 3.4 Diagnostic Technology Development
    • 3.4.1 Next Generation Sequencing Fuels a Revolution.
    • 3.4.2 Single Cell Genomics Changes the Picture
    • 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.4 CGES Testing, A Brave New World
    • 3.4.5 Biochips/Giant magneto resistance based assay

4. Companion Diagnostics Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
      • FDA Approval for FoundationOne®CDx
      • FDA finalizes CDx Guidance
      • QIAGEN Launches CDx Therascreen BRAF Test
      • Myriad Genetics Seeks Approval for Companion Diagnostic
      • ARUP Labs Seek PMA for Hemophilia Gene Therapy CDx
      • QIAGEN Builds on Global Collaboration with Amgen
      • Foundation Medicine nabs 19th companion Dx
      • Maze Therapeutics Uses CRISPR for Precision Medicine Companion Diagnostics
      • Myriad Wins Japanese Approval for BRACAnalysis
      • Fujitsu Improves Efficiency in Cancer Genomic Medicine
      • Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results
      • Takeda, Prometheus Enter IBD Drug-Companion Diagnostic Partnership
      • Thermo Fisher, Eli Lilly Ink CDx Collaboration in NSCLC, Thyroid Cancer
      • Roche VENTANA PD-L1 (SP142) Assay approved as companion diagnostic
      • Universal Genetic Testing for All Breast Cancer Patients
      • Exact Sciences buys Genomic Health
      • Biodesix Highlights Pipeline and Companion Diagnostic Development
      • Multi-Gene Liquid Biopsy Breast Cancer Panel
      • New Gene Panel Identifies High Risk Prostate Cancer
      • Guardant Health Liquid Biopsy Test to be Covered by EviCore
      • Inivata Completes £39.8M Series B Funding Round
      • Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance
      • CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials

5. Profiles of Key Players

  • 10x Genomics, Inc.
  • Abbott Diagnostics
  • AccuraGen Inc
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioIVT
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • Castle Biosciences, Inc.
  • CellMax Life
  • Cepheid (now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fabric Genomics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine (now Roche)
  • Freenome
  • FUJIFILM Wako Diagnostics
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd
  • Genomic Health
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Miltenyi Biotec
  • MIODx
  • miR Scientific
  • Molecular MD
  • MyCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Ortho Clinical Diagnostics
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostics
  • Screencell
  • Sense Biodetection.
  • Serametrix
  • Siemens Healthineers
  • Silicon Biosystems
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singulomics
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Todos Medical
  • Trovagene
  • Volition
  • Vortex Biosciences

6. The Global Market for Companion Diagnostics

  • 6.1 Global Market Overview by Country
    • 6.1.1 Table - Global Market by Country
    • 6.1.2 Chart - Global Market by Country
  • 6.2 Global Market by Application - Overview
    • 6.2.1 Table - Global Market by Application
    • 6.2.2 Chart - Global Market by Application - 2019/2024 Comparison
    • 6.2.3 Chart - Global Market by Application - 2019
    • 6.2.4 Chart - Global Market by Application -2024
    • 6.2.5 Chart - Global Market by Application - Share by Year
  • 6.3 Global Market Funding Source - Overview
    • 6.3.1 Table - Global Market by Funding Source
    • 6.3.2 Chart - Global Market Funding Source - 2019/2024 Comparison
    • 6.3.3 Chart - Global Market Funding Source - 2019
    • 6.3.4 Chart - Global Market Funding Source -2024
    • 6.3.5 Chart - Global Market Funding Source - Share by Year

7. Global Companion Diagnostic Markets - By Application

  • 7.1 Oncology
    • 7.1.1 Table Oncology - by Country
    • 7.1.2 Chart - Oncology Growth
  • 7.2 Neurology
    • 7.2.1 Table Neurology - by Country
    • 7.2.2 Chart - Neurology Growth
  • 7.3 Cardiology
    • 7.3.1 Table Cardiology - by Country
    • 7.3.2 Chart - Cardiology Growth
  • 7.4 Other Application
    • 7.4.1 Table Other Application - by Country
    • 7.4.2 Chart - Other Application Growth

8. Global Companion Diagnostic Markets - Funding Source

  • 8.1 Global Market Pharmaceutical
    • 8.1.1 Table Pharmaceutical - by Country
    • 8.1.2 Chart - Pharmaceutical Growth
  • 8.2 Global Market Venture
    • 8.2.1 Table Venture - by Country
    • 8.2.2 Chart - Venture Growth
  • 8.3 Global Market Clinical
    • 8.3.1 Table Clinical - by Country
    • 8.3.2 Chart - Clinical Growth
  • 8.4 Global Market Other Funding
    • 8.4.1 Table Other Funding - by Country
    • 8.4.2 Chart - Other Funding Growth

Appendices

  • I. United States Medicare System: January 2020 Clinical Laboratory Fees Schedule
  • II. Pharmacogenomic Biomarkers in Drug Labeling
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.